Major coup as Osbourn takes Mogrify chair
Cambridge cell therapy gamechanger Mogrify has secured a major bio industry coup by persuading Dr Jane Osbourn to become chair and join its scientific advisory board.
Osbourn is a globally renowned scientist in her own right and is chair of the BioIndustry Association in the UK. Until the AstraZeneca group rebrand recently she headed up the company’s MedImmune campus in Cambridge. Mogrify CEO Dr Darrin Disley believes the move will further accelerate the company’s march towards global greatness.
The company, which recently became anchor tenant at the new Tuspark Bio-Innovation Centre at Cambridge Science Park, aims to transform the development of cell therapies.
Dr Disley said: “Dr Osbourn is an inspirational leader in our industry who has developed numerous life-saving therapies and is renowned for her expertise in drug discovery and development among the global biotech and pharma communities.
“As chair, her guidance will be invaluable to Mogrify as we build a scalable infrastructure and the capability to develop novel cell therapies addressing musculoskeletal, auto-immune, cancer immunotherapy, ocular and respiratory diseases as well as generating and licensing novel IP related to cell conversions that exhibit safety, efficacy and scalable manufacturing profiles suitable for development as cell therapies.”
Dr Osbourn added: “Mogrify’s leadership team is of high commercial and scientific calibre; it was founded by leading academics in bioinformatics, machine learning and cell reprograming and the company has continued to strengthen its management and scientific teams with its recent move to state-of-the-art facilities on Cambridge Science Park.
“Mogrify’s platform has the ability to address many of the current challenges of cell therapy, which is an area of significant innovation and opportunity, and I am very excited to join the company at this stage in its development and look forward to its continued success.”
Dr Osbourn has over 30 years’ experience in biologics discovery and development. Most recently she was VP for Research and Development and site leader at MedImmune (AstraZeneca), formerly Cambridge Antibody Technology, where she contributed to the development of phage display technology.
She is a scientific leader in the field of antibody engineering and has made a significant contribution to the discovery and development of eight marketed drugs (including HUMIRA® and BENLYSTA®) and over 40 clinical candidates. Dr. Osbourn originated several key publications and patents and has presented at a number of parliamentary select committees. She was awarded an OBE this year for services to drug discovery, development and biotechnology.
She holds a doctorate from the John Innes Institute in Norwich, UK and a first-class degree in natural sciences from the University of Cambridge.